AzTrials
AzTrials

Benign Prostatic Hyperplasia (BPH) Requiring Surgical ResectionTURPNCT07669337

Conventional Fluid Management Versus Plethysmography Variability Index-based Goal-directed Fluid Management in Patients Undergoing Transurethral Resection of the Prostate

A study testing Conventional Fluid Management and Plethysmography Variability Index (PVI)-Guided Goal-Directed Fluid Management in people with Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection, run by Cairo University at 1 site in Egypt.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Transurethral resection of the prostate (TURP) is a widely performed surgical procedure for the management of benign prostatic hyperplasia. Because of the constant and frequently undetectable fluid exchange through the open prostatic venous sinuses, it is difficult to determine the precise amount of irrigating fluid… Read more about this study

Who is it for?
Ages 40 to 80 years, men onlyHealthy volunteers can take part
What is being tested?
Conventional Fluid Management and Plethysmography Variability Index (PVI)-Guided Goal-Directed Fluid Management
Could I receive a placebo?
No, everyone receives an active treatment
How many people
58 participants
Where
1 siteEgypt
Study dates
15 Mar 2016to Feb 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • • Male patients aged from 50 to 80 years Scheduled for elective TURP.
  • ASA Ⅰ, Ⅱ.

Who cannot join

  • • Cardiac arrhythmias (e.g., atrial fibrillation)
  • Left ventricular ejection fraction <40%
  • Chronic kidney disease (stage ≥ 3)
  • Hepatic dysfunction
  • Peripheral vascular disease
  • Prolonged procedures more than 2 hours or complicated procedures with severe bleeding affecting management (Severe bleeding will be defined as any of the following: a drop in hemoglobin of ≥ 2 g/dl, hemodynamic instability due to blood loss that requires blood transfusion).
  • Patients refuse to share in this study.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Cairo University Hospitals Anesthesia Department

    Cairo

Other trials in Egypt

About this study

Official title: Conventional Fluid Management Versus Plethysmography Variability Index-based Goal-directed Fluid Management in Patients Undergoing Transurethral Resection of the Prostate-a Randomized Controlled Trial

Transurethral resection of the prostate (TURP) is a widely performed surgical procedure for the management of benign prostatic hyperplasia. Because of the constant and frequently undetectable fluid exchange through the open prostatic venous sinuses, it is difficult to determine the precise amount of irrigating fluid absorbed after TURP surgery. Unpredictable intravascular volume changes may result from this. While over-resuscitation raises the risk of fluid overload, pulmonary edema, and cardiac events, under-resuscitation in older individuals can lead to hypotension and decreased organ perfusion. Fluid management in TURP has always depended on traditional techniques that employ clinical evaluations like blood pressure and heart rate monitoring or fixed-volume infusion procedures. By using advanced technologies, goal-directed fluid therapy (GDFT) methods continually monitor and evaluate a patient's physiological status in real time, modifying fluid dosage as necessary. A dynamic method for determining volume status, the plethysmography variability index (PVI) has been studied in numerous clinical settings and has proven reliable in predicting fluid responsiveness and acting as a fluid resuscitation guide

Read the detailed description

Transurethral resection of the prostate (TURP) is a widely performed surgical procedure for the management of benign prostatic hyperplasia, which affects a significant number of elderly men . TURP involves the removal of prostate tissue via the urethra and is associated with potential fluid shifts, blood loss, and hemodynamic instability. Effective fluid management during the procedure is crucial to ensure optimal patient outcomes, minimizing complications such as hypotension, acute kidney injury, and electrolyte imbalances .

Because of the constant and frequently undetectable fluid exchange through the open prostatic venous sinuses, it is difficult to determine the precise amount of irrigating fluid absorbed after TURP surgery. Unpredictable intravascular volume changes may result from this. While over-resuscitation raises the risk of fluid overload, pulmonary edema, and cardiac events, under-resuscitation in older individuals can lead to hypotension and decreased organ perfusion Fluid management in TURP has always depended on traditional techniques that employ clinical evaluations like blood pressure and heart rate monitoring or fixed-volume infusion procedures. Although the goal of these methods is hemodynamic stability, they might not be accurate in dynamically adapting to the specific requirements of each patient, especially when there are large fluid shifts. Furthermore, these approaches frequently overlook the fluctuations in patients' hemodynamic state in real time, which may result in either excessive or insufficient resuscitation By using advanced technologies, goal-directed fluid therapy (GDFT) methods continually monitor and evaluate a patient's physiological status in real time, modifying fluid dosage as necessary. A dynamic method for determining volume status, the plethysmography variability index (PVI) has been studied in numerous clinical settings and has proven reliable in predicting fluid responsiveness and acting as a fluid resuscitation guide .

The PVI has been shown to perform similarly to more invasive and expensive dynamic fluid assessment technologies (such as pulse pressure variation and stroke volume variation) . A small-sized randomized controlled trial (RCT) showed that PVI-directed fluid management reduced the lactate concentrations and improved fluid management in abdominal surgery recipients .

Nevertheless, the clinical outcomes of conventional fluid management with PVI-based GDFT were investigated in previous studies like colorectal surgeries and spine surgeries; we did not find a previous study investigating this strategy in elderly patients undergoing TURP surgery .

This randomized controlled trial (RCT) aims to compare the clinical outcomes of conventional fluid management with PVI-based GDFT in patients undergoing TURP. We hypothesize that PVI-guided fluid management will result in better intraoperative hemodynamic stability, a reduction in postoperative complications, and an overall improvement in patient recovery.

Study Procedures

  1. Randomization (in RCT only) Participants will be randomly assigned into two groups using a computer-generated randomization sequence:
  • Group Conventional: Conventional fluid therapy
  • Group PVI: PVI-guided goal-directed fluid therapy A double-blinded randomization technique will be employed, in which both the patient and the primary anesthesiologist responsible for routine intraoperative monitoring will be blinded to study. A study anaesthesiologist who will receive the randomization assignment and apply the allocated strategy (conventional fluid management or PVI-guided goal-directed therapy) will be present only to implement the fluid protocol and will not participate in data collection intraoperative, postoperative patient care, data collection, or outcome assessment.
  1. Study Protocol After history taking and examination of the labs (complete blood count, coagulation profile, blood chemistry including creatinine level , Alanine Aminotransferase (ALT) aspartate aminotransferase (AST), Na and K levels ) and airway of the patient, a written informed consent will be obtained, and all patients will fast for 8 hours.

Upon arrival to the operating room, an intravenous wide-bore 18 G venous cannula will be placed, premedication with 2 mg midazolam will be given, and standard monitoring (ECG, oxygen saturation, and non-invasive blood pressure) will be applied. A Masimo SET (Mighty-Sat 9900, Masimo Corporation, Irvine, CA, USA) will be connected to the index finger of the hand in each patient in both groups contralateral to that used for intravenous access and blood pressure and will be shielded with towels to avoid the effects of ambient light on its signals. The Masimo set will be connected to a smart device via Bluetooth, and the plethysmography waveforms will be recorded. Baseline vitals and PVI will be recorded in both groups and then will be recorded every 5 minutes till the end of the operation.

Skin sterilization will be done with the use of povidone-iodine solution to the lower back. This will be repeated 3 times. The area will be draped with sterile towels to maintain a sterile field. Then local anesthesia will be given after identification of the interspace (L4-L5). About 2-3 ml of 2% lidocaine will be injected along the trajectory of the planned spinal needle. Then wait for 1-2 minutes for the local anesthetic to take effect.

A spinal puncture will be performed at the L4-5 level with the patient in the sitting position. After the cerebrospinal fluid is detected, a standard dose of heavy bupivacaine 0.5% (15 mg) with fentanyl (25 μg) (total volume 3.5 ml) will be injected intrathecal via a 25-G Quinke needle. The sensory block level will be targeted: The T10 dermatome. Patients will be positioned supine with a slight head-up tilt to prevent high block. Moreover, 500 mL of acetated Ringer's solution, at an open co-loaded infusion, will be administered over 10 minutes. Hypotension will be defined as a reduction in MAP to ≤ 75% from baseline. Bradycardia (HR < 50). Rescue medication will be given for hypotension (ephedrine, 6 mg, IV) and bradycardia (atropine, 0.6 mg, IV).

Intraoperative monitoring will be standard monitors: ECG, non-invasive blood pressure (NIBP), and pulse oximetry. PVI monitor for Group P heart rate, mean arterial pressure (MAP), SpO₂, and PVI recorded every 5 minutes.

*Standardization of PVI measurements and handling of lithotomy positioning:-*

  • Baseline plethysmographic measurements (PVI and Perfusion Index [PI]) will be recorded with the patient supine prior to spinal anaesthesia and before any leg manipulation.
  • After induction of spinal anaesthesia (and after the sensory level is confirmed and hemodynamics have stabilized for 5 minutes), PVI will again be recorded in the supine position.
  • Immediately after positioning to lithotomy, PVI and PI will be recorded at 2 minutes and 5 minutes after positioning. For any PVI value used to trigger fluid administration, we will use the average of consecutive PVI readings over a 60-120 second window to reduce beat-to-beat/artifact variability.
  • PVI-guided interventions will not be triggered during active leg manipulation or while the surgeon is changing leg position. If leg position is changed during surgery, a 2-minute stabilization period will be observed before taking new PVI values used for decisions .

Fluid Management

Group Conventional:

  • Maintenance fluid with Ringer's acetate at 1 mL/kg/h all through the operation .
  • MAP will be measured every 5 min.
  • If the MAP is ≥75% of the baseline, 1 ml/kg/hr will be continued.
  • If the MAP is ≤75% of the baseline, an additional 250 mL of 0.9% NaCl bolus will be given.
  • After a fluid bolus, if the MAP ≥ 75% of the baseline, a 1 ml/kg/hr will be continued.
  • If the MAP is still less than 75% of the baseline ephedrine IV bolus (6 mg), repeat every 5 minutes till the MAP is ≥ 75% of baseline.

Group PVI:

  • Maintenance fluid with Ringer's acetate at 1 mL/kg/h all through the operation .
  • The PVI will be measured every 5 min.
  • If the PVI ≤ 13%, we will check the MAP; if the MAP ≥ 75% of the baseline, 1 ml/kg/hr will be continued.
  • If the MAP is ≤75% of the baseline (and the PVI ≤ 13%), an ephedrine IV bolus (6 mg) will be given and repeated every 5 min till the MAP is ≥ 75% of the baseline.
  • If the PVI ≥ 13%, we will check the MAP. If the MAP ≥ 75% of the baseline, a 250 mL bolus of 0.9% NaCl will be given and repeated every 5 min till PVI ≤ 13%.
  • If the MAP is less than 75% (and PVI ≥ 13%) of the baseline, a 250 mL bolus of 0.9% NaCl will be given and repeated every 5 min till PVI ≤ 13%, plus an ephedrine IV bolus (6 mg) repeated every 5 min till MAP ≥ 75% of baseline.

Diuretics will not be administered routinely and will be reserved for patients who develop clinical evidence of fluid overload or pulmonary congestion . Lung ultrasound will be performed at the end of the procedure. In such cases, an intravenous dose of furosemide 1mg/kg will be administered , until lung ultrasound confirms resolution of pulmonary congestion. Lung ultrasound will be performed after 1 hour as the diuretic effect of furosemide is established within 15 minutes and the peak effect occurs within the first half hour . These patients will be recorded as a subgroup.

Being tested
Conventional Fluid Management, Plethysmography Variability Index (PVI)-Guided Goal-Directed Fluid Management
Keywords
begnin prostatic hyperplasia, transurethral resection of the prostate
Medical subject headings
Prostatic Hyperplasia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Conventional Fluid ManagementOther

    Participants will receive conventional intraoperative fluid management according to the study protocol, based on mean arterial pressure (MAP) monitoring and fluid administration as clinically indicated.

  • Plethysmography Variability Index (PVI)-Guided Goal-Directed Fluid ManagementOther

    Participants will receive intraoperative fluid management guided by Plethysmography Variability Index (PVI) measurements according to the study protocol, with fluid administration adjusted based on PVI values and hemodynamic parameters.

Study groups in NCT07669337
Study groupRoleWhat they receive
Conventional Fluid Management.Active comparatorParticipants will receive conventional intraoperative fluid management according to the study protocol, based on mean arterial pressure (MAP) monitoring and fluid administration as clinically indicated.
Receives: Other: Conventional Fluid Management
PVI-Guided Goal-Directed Fluid ManageExperimentalParticipants will receive intraoperative fluid management guided by Plethysmography Variability Index (PVI) measurements according to the study protocol, with fluid administration adjusted based on PVI values and hemodynamic parameters.
Receives: Other: Plethysmography Variability Index (PVI)-Guided Goal-Directed Fluid Management

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The total amount of intraoperative crystalloid administered by each group.

    the amount of crystalloids bottles given to the patient during the intra operative period

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2026
  2. Study start15 Mar 2016
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completionFeb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomly assigned in a 1:1 ratio to one of two parallel groups: conventional fluid management or plethysmography variability index (PVI)-guided goal-directed fluid management during transurethral resection of the prostate (TURP). Outcomes will be compared between the two groups.
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
58 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07669337
Sponsor's protocol ID
MD-81-2026
Other IDs
MD-81-2026
Acronym
TURP
Status last verified
Jul 2026
First submitted
20 Jun 2026
Last updated
7 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No plan for sharing individual participant data has been developed for this study

Publications

  • Kadir Arslan ASŞ. Transurethral Resection of the Prostate (TURP) Syndrome: A Review of Perioperative Management. Comprehensive Medicine 2024;16(2):123-7.

  • Pandya DS. TURP Syndrome. Practical Guidelines on Fluid Therapy. Third ed2024. p. 537-43.

  • Tapscott AH, Hakim LS. Office-based management of impotence and Peyronie's disease. Urol Clin North Am. 2013 Nov;40(4):521-43. doi: 10.1016/j.ucl.2013.07.003. Epub 2013 Sep 3.

    PubMed 24182973

Questions about this trial

What is this clinical trial studying?

A study testing Conventional Fluid Management and Plethysmography Variability Index (PVI)-Guided Goal-Directed Fluid Management in people with Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The total amount of intraoperative crystalloid administered by each group. (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07669337, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in